7 Hills Pharma

Name

7 Hills Pharma

Legal name

7 Hills Pharma Inc.

Website

https://7hillspharma.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Immuno-oncology biopharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Oncology & Hematology Pharmaceuticals (HLAIAAAC)

akta.pro secondary industry

Transplantation & Advanced Therapies Pharmaceuticals (incl. Cell & Gene Therapies) (HLAIAAAO)

Keywords

• Integrin agonist therapy
• Cancer immunotherapy drugs
• Checkpoint inhibitor resistance
• Stem cell transplant enhancement
• Small molecule immunostimulants

Headquarters

HQ city

Houston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Licensing and Partnership Revenue: 7 Hills Pharma generates revenue through licensing its integrin activator technology to larger pharmaceutical companies for clinical development and commercialization. The company seeks partnerships with vaccine and immuno-oncology developers.
2. Nondilutive Grant Funding: The company has received over $34 million in nondilutive grant funding from NIH institutions (NIAID, NHLBI, NCI) and CPRIT to fund clinical development without diluting equity.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

7 Hills Pharma is a clinical-stage drug development company advancing first-in-class oral small molecule integrin agonists (Alintegimod/7HP349 and 7HP935) designed to enhance immune responses for cancer immunotherapy and hematopoietic stem cell transplantation. The company's pipeline targets anti-PD-1-resistant solid tumors, acute leukemias, genetic bone marrow disorders, and infectious disease vaccines including COVID-19, influenza, and Chagas disease.

Product overview

7 Hills Pharma is a clinical-stage drug development company advancing two first-in-class integrin-targeted small molecule agonists: Alintegimod (formerly 7HP349) for overcoming immunotherapy resistance in solid tumors and hematological malignancies, and 7HP935 for improving cell and gene therapy outcomes in hematopoietic stem cell transplantation. The company's proprietary platform leverages allosteric integrin activation to enhance antigen-specific immune responses when combined with checkpoint inhibitors, vaccines, or cell-based therapies. Additionally, the company developed THI0019, an early VLA-4 integrin agonist for stem cell therapy applications.

Differentiator

Problem solved

Functional benefit

Brands

• Alintegimod: First-in-class dual LFA-1 and VLA-4 agonist designed to overcome anti-PD-1 resistance in solid tumors when used with immune checkpoint inhibitors. Formerly known as 7HP349.
• 7HP935

Products and services

• Alintegimod (formerly 7HP349) First-in-class, dual LFA-1 and VLA-4 agonist oral small molecule designed to be used in combination with immune checkpoint inhibitors to safely overcome resistance to anti-PD-1 drugs in solid tumors. Currently enrolling patients in a Phase 1b/2a clinical trial for aPD-1-resistant solid tumors, with FDA Fast Track and Orphan Drug designations for advanced melanoma.
• 7HP935 First-in-class small molecule gene therapy enhancer designed to improve the effectiveness of CD34+ cell-based therapies for the treatment of acute leukemias and genetic disorders of the bone marrow. Currently undergoing IND-enabling studies to support a Phase I trial in hematopoietic stem cell transplantation, with focus on reducing graft failure and addressing racial disparities in donor matching.
• THI0019 First small molecule agonist of VLA-4 integrin (α4β1) designed to enhance progenitor cell adhesion and improve stem cell therapy outcomes. Generated via structural modifications to a previously identified α4β1 antagonist.

Quantifiable outcome

• Phase I trial completed with no treatment-related adverse events at exposures exceeding 9x therapeutic levels
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• MD Anderson Cancer CentercoreStrategic or Co-development Partner · 18 May 2022Collaborative research with Yared Hailemichael, Ph.D. and team leading to publication in Journal of Clinical Investigation demonstrating how 7HP349 converts cold tumors to hot, T cell-enriched tumors.
• Texas Heart InstitutecoreStrategic or Co-development Partner · 14 September 2021Co-inventors and original developers of the integrin activator technology. 7 Hills partnered with THI in 2014 to commercially develop the technology. THI scientists Peter Vanderslice, Ronald J. Biediger, and Darren G. Woodside discovered the compound family using rational design based on integrin biology and structure.
• Johnson & Johnson Innovation – JLABS (Blue Knight)coreStrategic or Co-development Partner · 1 January 2020Selected participant in Blue Knight collaboration with BARDA to help battle COVID-19 pandemic. One of seven companies in US, Canada, and Europe in the program.
• Catalent Pharma SolutionsminorImplementation/ SI/ Consulting Partner · 1 January 2020Manufacturing partnership for scalable production of 7HP349. Catalent's softgel site in St. Petersburg, Florida has capacity for up to 8 billion capsules annually.
• Eurofins AdvinusminorImplementation/ SI/ Consulting Partner · 1 January 2020Manufacturing partnership for drug development and production scale-up.
• Lipoid LLCminorImplementation/ SI/ Consulting Partner · 1 January 2020Manufacturing partnership for formulation and production of 7HP349.
• University of Texas Medical Branch (UTMB)coreStrategic or Co-development PartnerCollaboration with Dr. Nisha Garg's laboratory for Chagas disease vaccine development. Joint research published in Nature Partner Journal Vaccines demonstrating 7HP349 as vaccine adjuvant.
• UTHealth (University of Texas Health Science Center at Houston)minorStrategic or Co-development PartnerCollaboration with Professor Jeffrey Actor to develop 7HP349 as oral immunostimulant for COVID-19 and influenza vaccinations.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Werewolf Therapeutics: Clinical-stage immuno-oncology company developing first-in-class conditionally activated therapeutics. Comparable as a small, venture-backed IO biotech with a novel mechanism platform targeting solid tumor resistance and a similar development stage.
• Corvus Pharmaceuticals: Clinical-stage biopharma developing immune modulator therapies for cancer, including adenosine and ITK pathways. Comparable in target indication (PD-1-resistant solid tumors) and small-cap clinical-stage profile.
• Surface Oncology: Clinical-stage immuno-oncology company focused on next-generation antibodies targeting the tumor microenvironment. Comparable as a small-cap IO biotech pursuing combinations with checkpoint inhibitors.
• Jounce Therapeutics: Clinical-stage immuno-oncology company developing novel immunotherapies including PD-1 resistance approaches. Comparable clinical-stage IO profile and solid tumor focus targeting checkpoint resistance.
• Apexigen: Clinical-stage immuno-oncology company developing CD40 agonist antibodies and other innate immune activators. Comparable as a small clinical-stage biotech using immune activation to overcome checkpoint resistance.
• Compugen: Clinical-stage immuno-oncology company leveraging computational discovery to identify novel immune targets, including combos with checkpoint inhibitors. Comparable clinical-stage IO platform model.
• Pyxis Oncology: Clinical-stage oncology company developing antibody-drug conjugates and immunotherapies for difficult-to-treat cancers. Comparable clinical-stage, small-cap oncology profile with pipeline diversification.

Broad incumbents

• Bristol-Myers Squibb: Global pharmaceutical leader with deep immuno-oncology franchise including Opdivo and Yervoy. Sets the competitive bar in PD-1-resistant melanoma and is a logical potential licensing or acquisition partner for 7 Hills Pharma.
• Merck & Co. Global pharma leader with Keytruda checkpoint inhibitor franchise, actively pursuing combination strategies in PD-1-resistant tumors. Represents both a competitive threat and a potential acquirer for integrin-based combination agents.

Emerging players

• Adaptimmune Therapeutics: Clinical-stage cell therapy company developing engineered TCR therapies for solid tumors. Comparable clinical-stage oncology profile with cell therapy focus overlapping 7 Hills' 7HP935 program in hematologic malignancies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/7-hills-pharma-llc

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds4 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 7 Hills Pharma